HD Biosciences Co., Ltd. (HDB), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine announced the new partnership to co-develop potential anti-cancer drugs.
InvitroCue, a provider of innovative products and services for in vitro DMPK, in vitro toxicology and digital pathology, and HD Biosciences (HDB), a biology-focused preclinical drug discovery contract research organisation (CRO), have signed a collaboration agreement.
HD Biosciences Co., Ltd. (HDB), a leading biology-focused preclinical Contract Research Organization (CRO) based in Shanghai, announced that it will exhibit at the 2014 MipTec Conference & Exhibition, Europe's leading event for Drug Discovery and Life Sciences Research, September 23-25, 2014, in Basel, Switzerland.
HD Biosciences, Co., Ltd. (HDB), a leading biology-focused Contract Research Organization (CRO) in Shanghai, hosted its newly initiated Partners-Group Meeting (PGM) in Shanghai, on Friday, June 6, 2014.
HD Biosciences Co., Ltd. (HDB) and E. J. Corey Institute of Biomedical Research (CIBR) announced that they have reached a risk-sharing agreement on collaborative drug discovery and development in the therapeutic areas of infectious diseases, metabolic diseases, and oncology.
HD Biosciences, Corp. (HDB), a leading biology-focused Contract Research Organization (CRO) in Shanghai, announced that it will host its newly initiated Partners Group Meeting (PGM) in Shanghai, on Friday June 6, 2014.